Adagene's EBIT per Share for the
six
months ended in Dec. 2025 was €-0.08.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.32.
During the past 3 years, the average EBIT per Share Growth Rate was 38.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 20.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Adagene's EBIT per Share or its related term are showing as below:
FRA:978'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -53.1 Med: 19.1 Max: 38.4
Current: 38.4
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Adagene was 38.40% per year. The lowest was -53.10% per year. And the median was 19.10% per year.
FRA:978's 3-Year EBIT Growth Rate is ranked better than 78.16% of 1172
companies
in the Biotechnology industry
Industry Median: 15.35
vs FRA:978: 38.40
Adagene's EBIT for the
six
months ended in Dec. 2025 was €-3.66 Mil.
Adagene (FRA:978) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Adagene EBIT per Share Related Terms
Adagene EBIT per Share Historical Data
* Premium members only.
The historical data trend for Adagene's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.32
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adagene (FRA:978) has a EBIT per Share of €-0.32 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Adagene and its competitors. According to the industry distribution chart, Adagene ranks #256 out of 1172 companies in the Biotechnology industry, placing it in the top 21.8%.
Is Adagene's EBIT per Share too high?
Adagene's current EBIT per Share is €-0.32. Based on the distribution chart, Adagene ranks #256 out of 1172 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Adagene has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Adagene's EBIT per Share compare to RNAC and LYEL?
According to the Biotechnology industry distribution chart, Adagene ranks #256 out of 1172 companies for EBIT per Share. This places Adagene in the top 22% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.35, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Adagene and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adagene's current EBIT per Share is €-0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagene stock overvalued right now?
Adagene (FRA:978) has a current EBIT per Share of €-0.32. The stock's GF Value™ is €11.97, compared to a current price of €3.34 — trading 72.1% below its estimated fair value. The current EBIT per Share is €-0.32. Adagene's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Adagene (FRA:978), the current EBIT per Share is €-0.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adagene (FRA:978) Overvalued in 2026?
Based on GuruFocus' analysis, Adagene stock appears to be undervalued.
The current stock price of €3.34 is trading 72.1% below its estimated GF Value™ of €11.97.
Key valuation signals for FRA:978:
EBIT per Share: €-0.32
GF Value™: €11.97 vs. price of €3.34 (72.1% below fair value)
No single metric tells the full story. See the FRA:978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
42GF Score
Get the complete analysis for FRA:978
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:978 has been successfully added to your 
